NASDAQ · MYNZ
Healthcare · Medical - Diagnostics & Research
$0.84
Up+$0.03 (+0.84%)
Updated Sep 20, 2026, 12:15 PM
SID Score
3.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
MYNZ does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning MYNZ.
MYNZ research
Company profile and research snapshot.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Feb 14, 2025 | Maxim Group | Buy | — |
| Nov 25, 2024 | HC Wainwright & Co. | Neutral | — |
| Apr 12, 2024 | Cantor Fitzgerald | Neutral | — |
| Mar 6, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 21, 2023 | Cantor Fitzgerald | Neutral | — |
No generated briefing is available yet.
Benzinga · Feb 24, 2026
Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the renowned Digestive Disease Week (DDW) 2026 in
Benzinga · Feb 17, 2026
Yahoo · Feb 17, 2026
Company to Focus on Pancreatic Cancer Detection Business in the U.S., Strategic Asset Sales and Future Strategic TransactionBERKELEY, Calif. and MAINZ, Germany, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, announced a series of strategic transactions designed to strengthen its liquidity position, transition the business to a focus on its pancreatic cancer detection program in the U.S., a
Benzinga · Feb 17, 2026
Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, announced a series of strategic transactions designed to strengthen its liquidity position,
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MYNZ.
